Figure 6.
The effect of the combination of BVAC-K1117 with anti-PD-L1 antibody therapy on CT26/HER2 tumor-bearing mice. We inoculated 5 × 105 CT26/HER2 cells into naïve BALB/c mice, and vaccinated the mice with the indicated therapy on days 5 and 10 for the first cycle and on days 20 and 25 for the second cycle (A,B). The dose per treatment of BVAC was 2 × 106 cells per mouse and anti-PD-L1 antibody (MIH5) was 300 μg per mouse. All data are representative of two independent experiments (*** p < 0.001).